Injuries are part of living. Scrapes, fractures, and scar healing remind us that the body can repair itself. However, some wounds go deeper, beyond what nature and conventional treatments can do. For instance, when you have an injury in complex or protected areas of the body like the brain and spinal cord, there is a critical lack of effective, targeted, and non-invasive treatments. While traditional drug delivery systems can manage symptoms, they don’t recover function.
NurExone Biologic Inc. was founded on the idea that recovery from such complex injuries shouldn’t be an impossible challenge. Instead of relying on invasive treatments, the company uses the body’s most sophisticated repair systems: exosomes – microscopic messengers that cells use to communicate and heal. Through its proprietary ExoTherapy platform, the company loads these precision biological messengers with treatments for Central Nervous System (CNS) injuries – repairing tissue and recovering function, something once thought impossible.
Envisioning a Novel Healing Paradigm
NurExone Biologic was born out of research at the Technion – Israel’s Institute of Technology and Tel Aviv University, driven by the belief that the body’s own communication system could reveal itself as a breakthrough for healing and regeneration. The vision found a corporate structure with the recruitment of Lior Shaltiel, CEO and Director. An entrepreneur and an award-winning scientist with extensive multidisciplinary international experience, Lior believed exomes hold immense potential and could become the “ultimate drug delivery system”. He joined the company and began to translate the company’s research into targeted nervous system therapies, where medicine has made little progress for decades.
Under the leadership of Lior and his management team, the company is pioneering the development of loaded exosome therapies for CNS injuries. He understands that spinal cord injuries and optic nerve damage know no boundaries. The company receives inquiries from patients across Europe, the U.S., Asia, and even Iran, all looking to recover lost sensory or motor function, improve their lives and reclaim their independence. This global need guides every step of NurExone Biologic, combining cutting-edge science with a profound commitment to restoring lives.
Advancing Regeneration Through Precision Delivery
At the heart of NurExone Biologic’s mission is its ExoTherapy platform – a precision system that loads exosomes with therapeutic molecules that will be administered minimally-invasively. Its lead candidate, ExoPTEN – the company’s proprietary nanodrug, combines exosome-driven neural regeneration with siRNA for PTEN inhibition to reduce inflammation, offering a rare synergy of repair and protection for CNS injuries. Beyond ExoPTEN, the platform holds potential for additional regenerative and aesthetic applications, making it a versatile engine for innovation.
Technology drives every aspect of NurExone Biologic’s work. Proprietary exosome loading methods preserve vesicle integrity while ensuring therapeutic siRNA is accessible and potent. A secure production process provides a strong IP moat, ensuring both scalability and consistent quality. The company also acquired a Master Cell Bank, which is its stem-cell source for its cell-free exosomes. “Manufacturing and scaling are one of the greatest challenges in biotech. The Master Cell Bank established the foundation for reproducible, GMP-grade manufacturing,” explains Lior. It ensures batch-to-batch consistency, a critical regulatory and commercial milestone that many companies struggle to achieve.
Industry Landscape and Growth Outlook
The field of exosome-based therapies is advancing at an exponential pace, evolving from early-stage discoveries towards commercialization. The company’s lead candidate, ExoPTEN, targets patients suffering from acute spinal cord injuries (SCIs) sustained through work-related incidents, sports, and other traumatic events. In preclinical studies, ExoPTEN fully restored motor function and blood flow in spinal cord injury models, with all treated animals regaining locomotion at high doses using the CatWalk XT system. The breakthrough demonstrates its regenerative potential and functional recovery following the brief intranasal administration.
The incidence of and burden of SCI have increased substantially over the past decade, with around 90% resulting from trauma. In the U.S., recent data estimates about 18,000 new traumatic spinal cord injury (SCI) cases per year (MSKTC 2024). Globally, there were an estimated 0.9 million incident SCI cases in 2019, both traumatic and non-traumatic (Lippincott Journals, 2022). These injuries impose immense personal and financial burdens on patients and healthcare systems alike, creating a substantial market opportunity for effective regenerative treatments. As the therapy advances toward clinical readiness, the company plans to establish Exo-Top, its U.S. subsidiary, to produce GMP-grade naïve exosomes for its own use and for research, aesthetic, and regenerative markets, driving both medical and commercial growth.
Innovation, Research & Manufacturing Excellence
Given NurExone Biologic works with breakthrough technologies, no wonder the company heavily invests in R&D. “We have raised over $18 million, with the majority invested directly into research and development,” reveals Lior. This commitment has yielded compelling and robust preclinical data in both spinal cord and optic nerve injury models, validating ExoPTEN’s therapeutic potential and paving the way toward first-in-human trials.
These substantial investments also strengthen NurExone Biologic’s manufacturing capabilities. Unlike traditional cell-based therapies, which require massive, costly facilities and labour-intensive handling of living cells, exosome production is efficient and linear. It eliminates the need for large bioreactors or complex cell expansion, allowing the company to meet increasing clinical and commercial demand through compact, cost-effective facilities while maintaining consistent quality and minimizing waste.
A Culture of Synergy and Purpose
At NurExone Biologic, leadership is defined by synergy. “We are a team that collaborates seamlessly across science, regulation, and strategy,” says Lior. The company’s Head of R&D, Dr. Tali Kizhner, and Director of Clinical and Regulatory Affairs, Dr. Ina Sarel, embody this spirit of collective excellence. Together, they represent a model of leadership that values collaboration over hierarchy and execution over titles, ensuring that every decision serves both scientific integrity and patient outcomes.
The team also stands out for its purpose-driven mindset. Every member of the team understands the profound impact their work could have on patients who currently have few or limited treatment options. This shared mission fuels not only innovation but also deep emotional investment towards their ultimate goal to redefine the future of regenerative medicine.
Leading a Bold Change in Medicine
NurExone Biologic began in 2020, and over the past 5 years, the company is carving a role for its ExoTherapy platform. The modular system is capable of generating diverse exosome-based treatments for multiple indications. It’s first candidate, ExoPTEN, has already produced remarkable preclinical results across three major therapeutic areas: spinal cord injury, optic nerve regeneration, and early facial nerve recovery. The versatility gives the company a significant edge, reinforced by scientific validation and a growing patent portfolio that protects its breakthrough innovation.
Building on this, the company is actively expanding through strategic partnerships. The company is pursuing collaborations that leverage exosomes as delivery vehicles for a variety of therapeutic molecules, while also supplying naïve exosomes for aesthetic and healing injuries. “Our collaboration with Sheba Medical Center, which is ranked #8 in the world by Newsweek for 2025 and #9 in the world for ‘Smart Hospitals’ in 2026, and the Goldschleger Eye Institute has been instrumental in validating our optic nerve injury application,” highlights Lior. These efforts are positioning the company at the forefront of leading a bold change.
Charting the road to new possibilities
NurExone Biologic stands at the forefront of a new era in regenerative medicine. Over the next five years, the company aims to advance ExoPTEN into clinical studies and establish large-scale GMP production in the U.S. through its Exo-Top subsidiary. Exo-Top will serve as a hub for high-quality naïve exosome supply in regenerative and aesthetic applications, creating a bridge between scientific discovery and commercial opportunities.
Through these milestones, NurExone aims to establish a new clinical standard for exosome-based therapies and demonstrate that even conditions previously deemed irreversible can, with the right innovation, be reversed.
NurExone Biologic Inc. on Social Media
Business Talk is a digital business magazine that caters to CEOs, Entrepreneurs, VC, and Corporates. While working with entrepreneurs and business executives, we focus not only on their achievements. Our mission is to shed light on business entities, including their innovations, technological benchmarks, USPs, and milestones/accolades.
